🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 10% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size
Fat/Fatty Acid Product Type
10% Evidence Coverage

Supplement Facts — Evidence Check

8 mg (2% DV)
📊 Market median: 99.0mg (503 products) 📚 12 studies (Tier A: 0, B: 3)
RDA 700mg This product: 8mg UL 4000mg
Potassium
3 mg (1% DV)
Phosphatidyl Serine Complex
500 mg
Alpha-Linolenic Acid
10 mg
Linoleic Acid
85 mg
Oleic Acid
15 mg
Palmitic Acid
27 mg
Stearic Acid
6 mg
Capric Acid
51 mg
Caprylic Acid
120 mg

Other Ingredients

Soybean Oil Gelatin Glycerin Water

Label Claims — Verification

All Other
All Other (98% of products) Structure/Function (89% of products) Nutrient (76% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: As a dietary supplement, adults take one (1) capsule, one (1) to three (3) times daily with meals, or as directed by a health care professional.

⚠️ Warnings & Precautions

Keep out of reach of children.

🧪 Formulation Notes

Contains No Added sugar, salt, dairy, yeast, wheat, corn, soy, preservatives, artificial colors or flavors.

Additional Information

"We Make It Better..."

#10120

QUALITY AND POTENCY GUARANTEED

Store in a cool, dry place and away from direct light.

Product Details

DSLD Entry Date 2013-03-25
Product Type Fat/Fatty Acid
Form Softgel Capsule
DSLD ID 19479
Data Updated 2026-04-11

Research Evidence

46 Research Sources
55 Avg Quality Score
23 Meta Analysis
7 Systematic Review
7 Rct
4 Clinical Trial
2 Other
1 Guideline
1 Regulatory Source
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2018
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2025
B Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
Meta Analysis The Cochrane database of systematic reviews 2011
B Calcium and phosphorus supplementation of human milk for preterm infants
Systematic Review The Cochrane database of systematic reviews 2017
B Radiographic and clinical outcomes of silicate-substituted calcium phosphate (SiCaP) bone grafts in spinal fusion: Systematic review and meta-analysis
Meta Analysis Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020
B ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium.
Guideline Clinical nutrition (Edinburgh, Scotland) 2018
B Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Annals of palliative medicine 2022
B Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia
Meta Analysis The Cochrane database of systematic reviews 2015
B The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Journal of nephrology 2022
B Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies
Meta Analysis Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2024
View all evidence for Phosphorus →

Compare Similar Products

View all Phosphorus products →